I can assure you, from talking to my colleagues, and state commissioners, that this guidance has created a lot of angst, and concern, and it is in conflict with our intent.

Mr. Secretary, we received a response to that letter at 1:24 a.m. this morning.

I was very surprised to see that your budget is again proposing to zero out this program.

I just, you know, when I look at your previous efforts to eliminate the University of Maine's Agricultural Lab altogether during the Obama administration, and restrict the use of potatoes, despite the Institute of Medicine's study, that…

It is important that the record be corrected on this issue.

you stated that 'you were under the impression you are providing indemnity for livestock in addition to fluid milk.'

I told you that in 2016 a dairy farmer in Arundel, Maine, had discovered that the milk that was being produced by his cattle contains some of the highest levels ever reported from a PFAS contaminant.

will you rescind or revise that memo?

We know that the agreement that was reached is going to expire this summer; do we anticipate there are going to be further disruptions?

What can we do to ensure that we follow the practice that we have always followed?

We don't want to see a gap.

Could you please explain to the subcommittee how the Department can justify arguing in court that the pandemic has subsided enough to warrant the termination of Title 42?

I hope that we will be able to fill it.

In Maine, we set a horrific new record, 636 people died from drug overdoses.

I fear it will discourage research and have an impact on the pipeline of drugs.

What concerns me in this case is not FDA's approach. I think you stayed within your lanes.

I have heard serious concerns that FDA is responding to some meeting requests with a 'written response only.'

Congress charged the FDA, not CMS, to be the agency responsible for evaluating the safety and efficacy of biomedical products.

In light of the decision by CMS, do you question the FDA's decisionmaking regarding Aduhelm's accelerated approval?

We have had a great success, I believe, and we have got another agency of the Federal Government that just absolutely cut our legs out from under us.

I rise today in support of the nomination of Ketanji Brown Jackson to be an Associate Justice on the U.S. Supreme Court. Based on my careful review of her record and experience, as well as my assessment of her character and judicial…

I hope, sirs, that you can understand our legitimate and unavoidable impatience. You express a great deal of anxiety over our willingness to break laws. This is certainly a legitimate concern. Since we so diligently urge people to obey the…

I rise today to honor Eric Cioppa, the superintendent of the Maine Bureau of Insurance, who recently retired after more than three decades of distinguished public service to the State of Maine. Throughout his time at the bureau, Eric's…

Dr. Esham accelerated approval is a critical regulatory pathway that provides timely review of treatments for patients with serious and life threatening conditions for which there is an unmet need.

More than half of the 400 million people in the world who are affected by rare diseases are children, and about one-third of those children will sadly die before the age of five.